BURLINGTON, Mass., June 28, 2018 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, announced at its 2018 Annual Meeting of Stockholders that Frederick M. Hudson was elected to the Company’s Board of Directors, replacing Abhay Gandhi, whose term on the Board ended. Mr. Hudson will act as an independent director and Chair the Audit Committee.
“We are pleased to announce the appointment of Fred to our Board,” commented John Tucker, president and chief executive officer of scPharmaceuticals. “Fred has a deep accounting and finance background and has served as audit chair for a number of other private and public healthcare companies. We look forward to his contributions. I would also like to thank Abhay for all of his contributions over the last two years. We are grateful for his time, efforts and dedication.”
Mr. Hudson brings to the scPharmaceuticals Board over 37 years of relevant experience in accounting and auditing as a longtime partner at KPMG, LLP. Prior to his retirement, Mr. Hudson was the partner in charge of KPMG’s largest healthcare industry audit practice located in the Mid-Atlantic region. Over his career, Mr. Hudson also held senior positions with KPMG in the area of due-diligence and mergers and acquisitions services where his work was focused on high-growth companies in the healthcare industry. Over the last twelve years, Mr. Hudson has been a director of a variety of public and private healthcare industry companies.
“I am enthusiastic and honored to join such an innovative company as scPharmaceuticals,” commented Frederick Hudson. “I am very excited about the technology and developing products that could reduce healthcare costs while delivering a better patient experience. I look forward to working with the Company on advancing these products.”
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that reduce healthcare costs and improve health outcomes. The Company develops products for the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit scPharmaceuticals.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, without limitation, the risks set forth under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 and its subsequent public filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Except as required by law, the Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
Troy Ignelzi, CFO, scPharmaceuticals Inc.
Christopher F. Brinzey, Westwicke Partners